ArticleArchivum immunologiae et therapiae experimentalis2020
Antibodies to Heat Shock Proteins 90α and 90β in Psoriasis.
Article in Archivum immunologiae et therapiae experimentalis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 22 citations in OpenAlex.
- Emerging perspectives in proteostasis: bridging mechanisms and therapeutics for human diseases.Signal transduction and targeted therapy · 2026Review
- RGRN-305, a novel Hsp90 inhibitor: a promising therapeutic option for inflammatory dermatologic diseases.Inflammopharmacology · 2026Review
- Heat Shock Protein 70 Deficient Mice Exhibit Reduced Psoriasis-like Skin Inflammation.Biomedicines · 2026Article
- Engineered Sulfonated Bacterial Cellulose Hydrogel with Dual Bioactive-Drug Delivery Functions for Precision Treatment of Psoriasis.Biomacromolecules · 2025Article
- Psoriasis, stem cells, and obesity: metabolic exploration for therapeutics.Journal of medicine and life · 2025Review
- The Role of Alarmins in the Pathogenesis of Rheumatoid Arthritis, Osteoarthritis, and Psoriasis.Current issues in molecular biology · 2024Review
- New and Emerging Oral/Topical Small-Molecule Treatments for Psoriasis.Pharmaceutics · 2024Review
- Dual role of autoantibodies to heat shock proteins in autoimmune diseases.Frontiers in immunology · 2024Review
- Article
- Review
- Extracellular Heat Shock Protein-90 (eHsp90): Everything You Need to Know.Biomolecules · 2022Review
- Analysis of the prognostic, diagnostic and immunological role of HSP90α in malignant tumors.Frontiers in oncology · 2022Article
- Does HSP90 play an important role in psoriasis?Postepy dermatologii i alergologii · 2021Article
- Plasmatic Levels of HSP90α at Diagnosis: A Novel Prognostic Indicator of Clinical Outcome in Advanced Lung Cancer Patients Treated With PD-1/PD-L1 Inhibitors Plus Chemotherapy.Frontiers in oncology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
One of many hypotheses of psoriasis pathogenesis supposes an overexpression of heat shock proteins (Hsps) in different skin layers and systemic immunologic response to them. Hsp90 is one of the most abundant chaperone in eukaryotic cells. The number of studies concerning the role of Hsp90 and anti-Hsp90 antibodies in etiopathogenesis of various diseases is also constantly expanding. Still, there are not many reports concerning potential involvement of this Hsp family or anti-Hsp90 immunization in pathomechanism of psoriasis. The aim of the study was the estimation of anti-Hsp90α and anti-Hsp90β IgG antibodies in the sera of the psoriatic patients at different phases of disease activity in comparison to the sera of healthy individuals. The study material consisted of sera from psoriasis patients (n = 80) in active phase and in the remission phase and healthy individuals (n = 80). Concentrations of anti-Hsp90α and anti-Hsp90β IgG antibodies were determined using ELISA technique. In the patients with psoriasis (both in the active phase of the disease and in the remission phase) concentrations of anti-Hsp90α antibodies were significantly higher than in healthy individuals and they correlated positively with psoriasis area severity index values. The mean concentrations of anti-Hsp90β antibodies in the psoriatic patients and healthy controls were comparable. The obtained results indicate an existence of increased immunological response to Hsp90α in psoriasis. It may suggest the role of the extracellular form of this chaperone and/or anti-Hsp90α antibodies in etiopathogenesis of this dermatosis. The inhibition of Hsp90α may represent a novel therapeutic approach to treat psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.